about
FXR is a molecular target for the effects of vertical sleeve gastrectomyGut-Brain Cross-Talk in Metabolic Control.Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice.Loss of melanocortin-4 receptor function attenuates HPA responses to psychological stressThe Pentapeptide RM-131 Promotes Food Intake and Adiposity in Wildtype Mice but Not in Mice Lacking the Ghrelin ReceptorHypothalamic leptin action is mediated by histone deacetylase 5.Oral L-arginine stimulates GLP-1 secretion to improve glucose tolerance in male miceThe GPCR, class C, group 6, subtype A (GPRC6A) receptor: from cloning to physiological function.Current and Emerging Treatment Options in Diabetes Care.Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists.Renaissance of leptin for obesity therapy.Reappraisal of GIP Pharmacology for Metabolic Diseases.Unimolecular Polypharmacy for Treatment of Diabetes and Obesity.The New Biology and Pharmacology of Glucagon.Robust GLP-1 secretion by basic L-amino acids does not require the GPRC6A receptor.Enhanced voluntary wheel running in GPRC6A receptor knockout mice.GLP-1/glucagon receptor co-agonism for treatment of obesity.Increased susceptibility to diet-induced obesity in GPRC6A receptor knockout mice.Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease.Fibroblast activation protein (FAP) as a novel metabolic target.Molecular Integration of Incretin and Glucocorticoid Action Reverses Immunometabolic Dysfunction and Obesity.Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice.Unforeseen role for glucocorticoids in combinatorial anti-obesity pharmacology.Alternatively activated macrophages do not synthesize catecholamines or contribute to adipose tissue adaptive thermogenesis.The L-α-amino acid receptor GPRC6A is expressed in the islets of Langerhans but is not involved in L-arginine-induced insulin release.Blood BDNF concentrations reflect brain-tissue BDNF levels across species.A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.The microtubule-associated protein 1A (MAP1A) is an early molecular target of soluble Aβ-peptide.Exercise increases circulating GDF15 in humans.Emerging Poly-Agonists for Obesity and Type 2 Diabetes.Animal models of obesity and diabetes mellitus.Determination of thyroid hormones in mouse tissues by isotope-dilution microflow liquid chromatography-mass spectrometry method.Time-resolved hypothalamic open flow micro-perfusion reveals normal leptin transport across the blood-brain barrier in leptin resistant mice.Anti-Obesity Therapy: from Rainbow Pills to PolyagonistsDivergent effects of resistance and endurance exercise on plasma bile acids, FGF19, and FGF21 in humansCoordinated targeting of cold and nicotinic receptors synergistically improves obesity and type 2 diabetesPublisher Correction: Coordinated targeting of cold and nicotinic receptors synergistically improves obesity and type 2 diabetesPirt deficiency has subtle female-specific effects on energy and glucose metabolism in miceCelastrol-Induced Weight Loss Is Driven by Hypophagia and Independent From UCP1Coordinated increase in skeletal muscle fiber area and expression of IGF-I with resistance exercise in elderly post-operative patients
P50
Q28236848-E4CBA004-5F6A-481E-91FA-DD73264A8448Q30235568-378CC7FB-B238-4E1E-AD46-431D35E66626Q33600478-DC2CEF90-8E56-45C7-8621-52F28CA73DC8Q33998181-62D64A1D-7C75-47A2-8210-1725335384FEQ35596484-345345AF-C79B-4246-81CB-F03C3C1ECFD5Q35938884-14A47A20-3391-476E-80F8-0459A12545E1Q37240144-1EF938B6-196A-48D5-982A-D35D524830ACQ38137171-0FC03E34-5A9C-45AE-BA7C-F0B7888E2BB1Q38436227-367895A7-57D8-4BC5-8ABF-8C27B852812AQ38543559-BA821F1F-89CA-434A-A11F-A365A747C97DQ38777443-416FB4B9-D6E4-4CCD-8D90-7A0E82CC3748Q38796531-52E195EF-5B5B-485A-B49D-2DD836398A24Q38895281-8FD4A6A6-B713-4B70-B51A-B987624C65AEQ38919742-E7C5D9F1-6F0B-4EE1-B030-47BDB82269CCQ39108617-D513E52B-285F-4317-8290-9AC3E00C1C42Q39417924-667E15FF-ADF4-4D10-8212-57F61A6FFB25Q39451553-62CCB79B-62B0-411D-B009-9D1830504A0BQ39463877-D170D6D5-DBDE-43C8-8EB7-96985C56AEAFQ40527924-F1A5E357-D6FE-45B9-A843-F9F3B2F00AA1Q41166927-F832CE07-C98F-4508-A323-7820C334EF9BQ41994678-59F8D17B-09C3-4BA1-A8ED-17344E339E37Q42004480-C8E5A057-C140-4B1B-89C4-18780260E3DDQ42105383-22FCD068-04CD-4BBF-981A-91B0F0C98E99Q42287782-D45B1823-4251-4DA1-9821-000A4A20E8D8Q44176174-1C7F9FAB-E89D-4CD3-8F59-DEB4E09CD096Q48138873-A389404A-AB5F-47AA-9F40-9FD5EB0D3FCDQ48246762-F1078A6C-1AFC-4453-B77A-A5B051C186F8Q48709443-2FF75725-1490-4C5B-8057-9FFDEBC32DFCQ49339915-C3DC21B3-34A0-4328-9240-5B7AB547659AQ49833881-C72CDBE5-EFD0-497A-99CD-36D095F979A1Q49952246-95E26A16-7059-4D96-AAD5-01FF8BC8EC5BQ50487428-8EB6B858-FF38-4988-9DE0-92664F75B65CQ53684394-C39E5996-E664-4C4D-93B8-A3C7781D3CF7Q57093513-C679FBB0-1FFB-4769-9103-FE80B5FE1792Q57112246-8B9A563F-49DF-4744-AFFD-470F1615F6EFQ57798868-F1E2698A-2049-4758-B644-D1F4D7D08FCCQ59336452-2F435CBA-C9AB-49C9-9F4B-40259B38E2BEQ64122591-C46BDC39-17E3-43A9-B8F8-E4C0362AB994Q64387663-3D096472-BC98-4C3F-8C87-023DAD165C2EQ82326836-AB846CCE-2B79-4C2B-B2FC-39FEBEA4E36F
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Christoffer Clemmensen
@ast
Christoffer Clemmensen
@en
Christoffer Clemmensen
@es
Christoffer Clemmensen
@nl
Christoffer Clemmensen
@sl
type
label
Christoffer Clemmensen
@ast
Christoffer Clemmensen
@en
Christoffer Clemmensen
@es
Christoffer Clemmensen
@nl
Christoffer Clemmensen
@sl
prefLabel
Christoffer Clemmensen
@ast
Christoffer Clemmensen
@en
Christoffer Clemmensen
@es
Christoffer Clemmensen
@nl
Christoffer Clemmensen
@sl
P1053
N-4680-2017
P106
P1153
35974829100
P21
P31
P3829
P496
0000-0003-2456-9667